文献速递神经肿瘤

家族性胶质瘤患者的肿瘤分子亚型分析

Molecular subtyping of tumors from patients with familial glioma.
PubMed 文献 · Neuro Oncol · 2018-01-01

研究对75个家族性胶质瘤家族的肿瘤组织进行分子分型,62例(83%)可分类为IDH野生型、IDH突变非共缺失型和IDH突变伴1p/19q共缺失型三种亚型,其分布与散发性胶质瘤无统计学差异(P=0.54)。10对家族内配对样本中7对分子亚型一致(κ=0.59),提示同一家族内患者可能发展为相同分子亚型的胶质瘤。

要点

  • 62/75例(83%)家族性胶质瘤可归入三种分子亚型。
  • 亚型分布:IDH野生型30例(48%)、IDH突变非共缺失21例(34%)、IDH突变伴1p/19q共缺失11例(19%)。
  • 家族性胶质瘤分子亚型分布与散发性胶质瘤无统计学差异(P=0.54)。

核心结论

  • 数据提示同一家族内患者所患胶质瘤为相同分子亚型,但家族性胶质瘤与散发性胶质瘤的分子亚型患病率未见差异。

研究设计与样本

  • 家族性胶质瘤研究(Gliogene)参与者提供胚系DNA样本,对部分家族性胶质瘤病例的福尔马林固定石蜡包埋肿瘤组织提取DNA进行分析。
  • 共分析75个家族的肿瘤组织,其中10个家族包含第二例受累家庭成员。
  • 采用第一代Affymetrix分子倒置探针(MIP)阵列获取拷贝数变异数据。

主要发现

  • 75例家族性胶质瘤中62例(83%)可分类为三种分子亚型。
  • 分子亚型患病率:IDH野生型30例(48%)、IDH突变非共缺失型21例(34%)、IDH突变伴1p/19q共缺失型11例(19%)。
  • 该分子亚型分布与散发性胶质瘤相比无统计学差异(P=0.54)。
  • 10对家族性胶质瘤配对样本中,7对分子亚型一致(κ=0.59),包括3对IDH突变非共缺失型、2对IDH野生型和2对IDH突变伴1p/19q共缺失型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Single-gene mutation syndromes account for some familial glioma (FG); however, they make up only a small fraction of glioma families. Gliomas can be classified into 3 major molecular subtypes based on isocitrate dehydrogenase (IDH) mutation and 1p/19q codeletion. We hypothesized that the prevalence of molecular subtypes might differ in familial versus sporadic gliomas and that tumors in the same family should have the same molecular subtype. METHODS: Participants in the FG study (Gliogene) provided samples for germline DNA analysis. Formalin-fixed, paraffin-embedded tumors were obtained from a subset of FG cases, and DNA was extracted. We analyzed tissue from 75 families, including 10 families containing a second affected family member. Copy number variation data were obtained using a first-generation Affymetrix molecular inversion probe (MIP) array. RESULTS: Samples from 62 of 75 (83%) FG cases could be classified into the 3 subtypes. The prevalence of the molecular subtypes was: 30 (48%) IDH-wildtype, 21 (34%) IDH-mutant non-codeleted, and 11 (19%) IDH-mutant and 1p/19q codeleted. This distribution of molecular subtypes was not statistically different from that of sporadic gliomas (P = 0.54). Of 10 paired FG samples, molecular subtypes were concordant for 7 (κ = 0.59): 3 IDH-mutant non-codeleted, 2 IDH-wildtype, and 2 IDH-mutant and 1p/19q codeleted gliomas. CONCLUSIONS: Our data suggest that within individual families, patients develop gliomas of the same molecular subtype. However, we did not observe differences in the prevalence of the molecular subtypes in FG compared with sporadic gliomas. These observations provide further insight into the distribution of molecular subtypes in FG.

来源:Neuro Oncol,查看原文。版权归原作者所有。

引用

  1. Ruiz VY, Praska CE, Armstrong G, et al. Molecular subtyping of tumors from patients with familial glioma. Neuro Oncol. 2018. PMID: 29040662. doi:10.1093/neuonc/nox192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。